Publications of the NRC
2026
- Toutes les publications – all years publications
- Tuberculose – Tuberculosis
- Mycobactéries atypiques – NTM
- Lèpre – Leprosy
- M. ulcerans – Buruli ulcer
Classification annuelle – voir ci dessous (by date, see below)
2019
Cliquer ici pour toutes les publications du CNR-MyRMA en 2019
1368488
{1368488:5FET4T2Q}
2019
1
art-libraries-society-of-north-america-arlisna-reviews
50
default
200
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%225FET4T2Q%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Petrella%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26%23x201C%3BOverall%20Structures%20of%20Mycobacterium%20Tuberculosis%20DNA%20Gyrase%20Reveal%20the%20Role%20of%20a%20Corynebacteriales%20GyrB-Specific%20Insert%20in%20ATPase%20Activity%26%23x201D%3B%20by%20St%26%23xE9%3Bphanie%20Petrella%20et%20al.%20%26lt%3Bi%26gt%3BStructure%26lt%3B%5C%2Fi%26gt%3B.%2027%2C%20no.%204%20%28avril%202019%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.str.2019.01.004%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.str.2019.01.004%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Overall%20Structures%20of%20Mycobacterium%20tuberculosis%20DNA%20Gyrase%20Reveal%20the%20Role%20of%20a%20Corynebacteriales%20GyrB-Specific%20Insert%20in%20ATPase%20Activity%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Petrella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Estelle%22%2C%22lastName%22%3A%22Capton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Raynal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9ment%22%2C%22lastName%22%3A%22Giffard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lien%22%2C%22lastName%22%3A%22Thureau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Bonnet%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pedro%20M.%22%2C%22lastName%22%3A%22Alzari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudine%22%2C%22lastName%22%3A%22Mayer%22%7D%5D%2C%22abstractNote%22%3A%22Despite%20sharing%20common%20features%2C%20previous%20studies%20have%20shown%20that%20gyrases%20from%20different%20species%20have%20been%20modified%20throughout%20evolution%20to%20modulate%20their%20properties.%20Here%2C%20we%20report%20two%20crystal%20structures%20of%20Mycobacterium%20tuberculosis%20DNA%20gyrase%2C%20an%20apo%20and%20AMPPNP-bound%20form%20at%202.6-%5Cu00c5%20and%203.3-%5Cu00c5%20resolution%2C%20respectively.%20These%20structures%20provide%20high-resolution%20structural%20data%20on%20the%20quaternary%20organization%20and%20interdomain%20connections%20of%20a%20gyrase%20%28full-length%20GyrB-GyrA57%292%20thus%20providing%20crucial%20inputs%20on%20this%20essential%20drug%20target.%20Together%20with%20small-angle%20X-ray%20scattering%20studies%2C%20they%20revealed%20an%20%5Cu201cextremely%20open%5Cu201d%20N-gate%20state%2C%20which%20persists%20even%20in%20the%20DNA-free%20gyrase-AMPPNP%20complex%20and%20an%20unexpected%20connection%20between%20the%20ATPase%20and%20cleavage%20core%20domains%20mediated%20by%20two%20Corynebacteriales-specific%20motifs%2C%20respectively%20the%20C-loop%20and%20DEEE-loop.%20We%20show%20that%20the%5Cu00a0C-loop%20participates%20in%20the%20stabilization%20of%20this%20open%20conformation%2C%20explaining%20why%20this%20gyrase%20has%20a%20lower%20ATPase%20activity.%20Our%20results%20image%20a%20conformational%20state%20which%20might%20be%20targeted%20for%20drug%20discovery.%22%2C%22date%22%3A%22avril%202%2C%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.str.2019.01.004%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS0969212619300048%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%220969-2126%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A57%3A01Z%22%7D%7D%5D%7D
“Overall Structures of Mycobacterium Tuberculosis DNA Gyrase Reveal the Role of a Corynebacteriales GyrB-Specific Insert in ATPase Activity” by Stéphanie Petrella et al. Structure. 27, no. 4 (avril 2019). https://doi.org/10.1016/j.str.2019.01.004.
2018
Cliquer ici pour toutes les publications du CNR-MyRMA en 2018
1368488
{1368488:5DABHW8P}
2018
1
art-libraries-society-of-north-america-arlisna-reviews
50
default
201
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%225DABHW8P%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cambau%20et%20al.%22%2C%22parsedDate%22%3A%222018-12-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26%23x201C%3BAntimicrobial%20Resistance%20in%20Leprosy%3A%20Results%20of%20the%20First%20Prospective%20Open%20Survey%20Conducted%20by%20a%20WHO%20Surveillance%20Network%20for%20the%20Period%202009%26%23×2013%3B15%26%23x201D%3B%20by%20E.%20Cambau%20et%20al.%20%26lt%3Bi%26gt%3BClinical%20Microbiology%20and%20Infection%26lt%3B%5C%2Fi%26gt%3B.%2024%2C%20no.%2012%20%28December%201%2C%202018%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2018.02.022%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2018.02.022%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Antimicrobial%20resistance%20in%20leprosy%3A%20results%20of%20the%20first%20prospective%20open%20survey%20conducted%20by%20a%20WHO%20surveillance%20network%20for%20the%20period%202009%5Cu201315%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Saunderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Matsuoka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20T.%22%2C%22lastName%22%3A%22Cole%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Kai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Suffys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20S.%22%2C%22lastName%22%3A%22Rosa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Williams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U.%20D.%22%2C%22lastName%22%3A%22Gupta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Lavania%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Cardona-Castro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Miyamoto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Hagge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Srikantam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Hongseng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Indropo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Vissa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20C.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Cauchoix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20K.%22%2C%22lastName%22%3A%22Pannikar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20a.%20W.%20D.%22%2C%22lastName%22%3A%22Cooreman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20R.%20R.%22%2C%22lastName%22%3A%22Pemmaraju%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Gillini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kriswamati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdul%20Rahim%22%2C%22lastName%22%3A%22Al-Samie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahamed%22%2C%22lastName%22%3A%22Issoufou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Tiendrebeogo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22AmriMiraju%22%2C%22lastName%22%3A%22Kingalu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andriamira%22%2C%22lastName%22%3A%22Randrianantoandro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anil%22%2C%22lastName%22%3A%22Kumar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurelie%22%2C%22lastName%22%3A%22Chauffour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aye%20Aye%22%2C%22lastName%22%3A%22Win%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Basudev%22%2C%22lastName%22%3A%22Pandey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20M.%22%2C%22lastName%22%3A%22Agrawal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christiana%22%2C%22lastName%22%3A%22Widaningrum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Schmotzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Kafando%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chuda%20Mani%22%2C%22lastName%22%3A%22Bhandari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cynthia%22%2C%22lastName%22%3A%22Sema%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20S.%22%2C%22lastName%22%3A%22Vidanagama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20M.%22%2C%22lastName%22%3A%22Scollard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Demmissew%22%2C%22lastName%22%3A%22Beyene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliane%20Faria%22%2C%22lastName%22%3A%22Morelo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20Dizaneh%22%2C%22lastName%22%3A%22Kassa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Enerantien%20Benoit%22%2C%22lastName%22%3A%22Ramarolahy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Claco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ernesto%20ES%22%2C%22lastName%22%3A%22Villalon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Famoussa%22%2C%22lastName%22%3A%22Sidibe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fatoumata%22%2C%22lastName%22%3A%22Sakho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fomba%22%2C%22lastName%22%3A%22Abdoulaye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francisco%20F.%22%2C%22lastName%22%3A%22Guilengue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fransesca%22%2C%22lastName%22%3A%22Gajete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gadde%20Rajan%22%2C%22lastName%22%3A%22Babu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gado%22%2C%22lastName%22%3A%22Moussa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Garib%20Das%22%2C%22lastName%22%3A%22Thakur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gemma%22%2C%22lastName%22%3A%22Cabanos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gouressi%22%2C%22lastName%22%3A%22Sock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Greame%22%2C%22lastName%22%3A%22Clugston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hany%22%2C%22lastName%22%3A%22Zaidy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Haruo%22%2C%22lastName%22%3A%22Watanabe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herman%20Joseph%22%2C%22lastName%22%3A%22Kawuma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irene%20Balenton%22%2C%22lastName%22%3A%22Mallari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabella%20Maria%20Bernandes%22%2C%22lastName%22%3A%22Goulart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Issoufou%22%2C%22lastName%22%3A%22Ahamed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Subbanna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Gabin%22%2C%22lastName%22%3A%22Houzeo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Norbert%20Mputu%22%2C%22lastName%22%3A%22Luengu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeanne%22%2C%22lastName%22%3A%22Bertolli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Lloyd-Owen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Matheu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20Pereira%22%2C%22lastName%22%3A%22Brunelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Camilo%20Beltran%22%2C%22lastName%22%3A%22Alzate%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kapil%20Dev%22%2C%22lastName%22%3A%22Neupane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katsunori%22%2C%22lastName%22%3A%22Osuga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kazuko%22%2C%22lastName%22%3A%22Yamaguchi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Khalid%22%2C%22lastName%22%3A%22Azam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Khin%20Maung%22%2C%22lastName%22%3A%22Lin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kodia%22%2C%22lastName%22%3A%22Momoudu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kyaw%22%2C%22lastName%22%3A%22Kyaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Landry%22%2C%22lastName%22%3A%22Bide%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Le%20Huu%22%2C%22lastName%22%3A%22Doanh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ley%20Huyen%22%2C%22lastName%22%3A%22My%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mahesh%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mamadou%22%2C%22lastName%22%3A%22Kodio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mamadou%22%2C%22lastName%22%3A%22Sidibe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mannam%22%2C%22lastName%22%3A%22Ebenezer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Aparecida%20de%20Faria%22%2C%22lastName%22%3A%22Grossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marivic%20F.%22%2C%22lastName%22%3A%22Balagon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marlience%22%2C%22lastName%22%3A%22Canlonon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Masahiko%22%2C%22lastName%22%3A%22Makino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maung%20Maung%22%2C%22lastName%22%3A%22Htoo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Md%20Jamsheed%22%2C%22lastName%22%3A%22Ahmed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mintsey-mi-Makuth%22%2C%22lastName%22%3A%22Nadine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florenda%20Orcullo%22%2C%22lastName%22%3A%22Roferos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hana%22%2C%22lastName%22%3A%22Krismawati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mya%22%2C%22lastName%22%3A%22Thida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Myo%20Thet%22%2C%22lastName%22%3A%22Htoon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20D.%22%2C%22lastName%22%3A%22Neupane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nhu%20Ha%20Nguyen%22%2C%22lastName%22%3A%22Phuc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22NguyenThi%20Hai%22%2C%22lastName%22%3A%22Van%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ngyuen%20Phuc%20Nhu%22%2C%22lastName%22%3A%22Hai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norisha%22%2C%22lastName%22%3A%22Ishii%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oke%22%2C%22lastName%22%3A%22Soe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%22%2C%22lastName%22%3A%22Amiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Omar%22%2C%22lastName%22%3A%22Tossou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ousmane%22%2C%22lastName%22%3A%22Konare%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20L.%22%2C%22lastName%22%3A%22Joshi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20V.%20Ranganadha%22%2C%22lastName%22%3A%22Rao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Padebettu%22%2C%22lastName%22%3A%22Krishnamurthy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20J.%22%2C%22lastName%22%3A%22Brennan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Phillipe%22%2C%22lastName%22%3A%22Busso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rajesh%22%2C%22lastName%22%3A%22Bhatia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mala%20Rakoto%22%2C%22lastName%22%3A%22Andrianarivelo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20R.%22%2C%22lastName%22%3A%22Ramdas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raoul%22%2C%22lastName%22%3A%22Chabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renato%22%2C%22lastName%22%3A%22Gusmao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rita%22%2C%22lastName%22%3A%22DjupuriIzwardy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rosa%20Castalia%20Franca%20Riberio%22%2C%22lastName%22%3A%22Soares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rupendra%22%2C%22lastName%22%3A%22Jhadav%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samira%22%2C%22lastName%22%3A%22Buhrer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sang-Nae%20Ray%22%2C%22lastName%22%3A%22Cho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shen%22%2C%22lastName%22%3A%22Jianping%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shinzo%22%2C%22lastName%22%3A%22Lzumi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sumana%22%2C%22lastName%22%3A%22Barua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sundeep%22%2C%22lastName%22%3A%22Chaitanya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvestre%20Marie%20Roget%22%2C%22lastName%22%3A%22Tiendrebeogo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tan%20Hau%22%2C%22lastName%22%3A%22Khang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20P.%22%2C%22lastName%22%3A%22Gillis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Toru%22%2C%22lastName%22%3A%22Mori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Vijayalakshmi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vedastus%20Deusdedit%22%2C%22lastName%22%3A%22Kamara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wang%22%2C%22lastName%22%3A%22Wei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20Cairn%20S.%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wei%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Woojin%22%2C%22lastName%22%3A%22Lew%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yasin%22%2C%22lastName%22%3A%22Al-Qubati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yasuhiko%22%2C%22lastName%22%3A%22Suzuki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoshio%22%2C%22lastName%22%3A%22Nanba%22%7D%5D%2C%22abstractNote%22%3A%22%26lt%3Bh2%26gt%3BAbstract%26lt%3B%5C%2Fh2%26gt%3B%26lt%3Bh3%26gt%3BObjectives%26lt%3B%5C%2Fh3%26gt%3B%26lt%3Bp%26gt%3BAntimicrobial%20resistance%20%28AMR%29%20is%20a%20priority%20for%20surveillance%20in%20bacterial%20infections.%20For%20leprosy%2C%20AMR%20has%20not%20been%20assessed%20because%20%26lt%3Bi%26gt%3BMycobacterium%20leprae%26lt%3B%5C%2Fi%26gt%3B%20does%20not%20grow%20%26lt%3Bi%26gt%3Bin%20vitro%26lt%3B%5C%2Fi%26gt%3B.%20We%20aim%20to%20obtain%20AMR%20data%20using%20molecular%20detection%20of%20resistance%20genes%20and%20to%20conduct%20a%20prospective%20open%20survey%20of%20resistance%20to%20antileprosy%20drugs%20in%20countries%20where%20leprosy%20is%20endemic%20through%20a%20WHO%20surveillance%20network.%26lt%3B%5C%2Fp%26gt%3B%26lt%3Bh3%26gt%3BMethods%26lt%3B%5C%2Fh3%26gt%3B%26lt%3Bp%26gt%3BFrom%202009%20to%202015%2C%20multi-bacillary%20leprosy%20cases%20at%20sentinel%20sites%20of%2019%20countries%20were%20studied%20for%20resistance%20to%20rifampicin%2C%20dapsone%20and%20ofloxacin%20by%20PCR%20sequencing%20of%20the%20drug-resistance-determining%20regions%20of%20the%20genes%20%26lt%3Bi%26gt%3BrpoB%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3BfolP1%26lt%3B%5C%2Fi%26gt%3B%20and%20%26lt%3Bi%26gt%3BgyrA%26lt%3B%5C%2Fi%26gt%3B.%26lt%3B%5C%2Fp%26gt%3B%26lt%3Bh3%26gt%3BResults%26lt%3B%5C%2Fh3%26gt%3B%26lt%3Bp%26gt%3BAmong%201932%20%281143%20relapse%20and%20789%20new%29%20cases%20studied%2C%20154%20%288.0%25%29%20%26lt%3Bi%26gt%3BM.%20leprae%26lt%3B%5C%2Fi%26gt%3B%20strains%20were%20found%20with%20mutations%20conferring%20resistance%20showing%20182%20resistance%20traits%20%2874%20for%20rifampicin%2C%2087%20for%20dapsone%20and%2021%20for%20ofloxacin%29.%20Twenty%20cases%20showed%20rifampicin%20and%20dapsone%20resistance%2C%20four%20showed%20ofloxacin%20and%20dapsone%20resistance%2C%20but%20no%20cases%20were%20resistant%20to%20rifampicin%20and%20ofloxacin.%20Rifampicin%20resistance%20was%20observed%20among%20relapse%20%2858%5C%2F1143%2C%205.1%25%29%20and%20new%20%2816%5C%2F789%2C%202.0%25%29%20cases%20in%2012%20countries.%20India%2C%20Brazil%20and%20Colombia%20reported%20more%20than%20five%20rifampicin-resistant%20cases.%26lt%3B%5C%2Fp%26gt%3B%26lt%3Bh3%26gt%3BConclusions%26lt%3B%5C%2Fh3%26gt%3B%26lt%3Bp%26gt%3BThis%20is%20the%20first%20study%20reporting%20global%20data%20on%20AMR%20in%20leprosy.%20Rifampicin%20resistance%20emerged%2C%20stressing%20the%20need%20for%20expansion%20of%20surveillance.%20This%20is%20also%20a%20call%20for%20vigilance%20on%20the%20global%20use%20of%20antimicrobial%20agents%2C%20because%20ofloxacin%20resistance%20probably%20developed%20in%20relation%20to%20the%20general%20intake%20of%20antibiotics%20for%20other%20infections%20as%20it%20is%20not%20part%20of%20the%20multidrug%20combination%20used%20to%20treat%20leprosy.%26lt%3B%5C%2Fp%26gt%3B%22%2C%22date%22%3A%222018%5C%2F12%5C%2F01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.cmi.2018.02.022%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.clinicalmicrobiologyandinfection.com%5C%2Farticle%5C%2FS1198-743X%2818%2930197-6%5C%2Fabstract%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221198-743X%22%2C%22language%22%3A%22English%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222019-04-03T22%3A28%3A25Z%22%7D%7D%5D%7D
“Antimicrobial Resistance in Leprosy: Results of the First Prospective Open Survey Conducted by a WHO Surveillance Network for the Period 2009–15” by E. Cambau et al. Clinical Microbiology and Infection. 24, no. 12 (December 1, 2018). https://doi.org/10.1016/j.cmi.2018.02.022.
2017
Cliquer ici pour toutes les publications du CNR-MyRMA en 2017
1368488
{1368488:EQSSDJFH}
2017
1
art-libraries-society-of-north-america-arlisna-reviews
50
default
202
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22EQSSDJFH%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maitre%20et%20al.%22%2C%22parsedDate%22%3A%222017-08-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26%23x201C%3BAre%20Moxifloxacin%20and%20Levofloxacin%20Equally%20Effective%20to%20Treat%20XDR%20Tuberculosis%3F%26%23x201D%3B%20by%20Thomas%20Maitre%20et%20al.%20%26lt%3Bi%26gt%3BJournal%20of%20Antimicrobial%20Chemotherapy%26lt%3B%5C%2Fi%26gt%3B.%2072%2C%20no.%208%20%28August%201%2C%202017%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdkx150%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdkx150%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Are%20moxifloxacin%20and%20levofloxacin%20equally%20effective%20to%20treat%20XDR%20tuberculosis%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Maitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gr%5Cu00e9goire%22%2C%22lastName%22%3A%22Petitjean%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Chauffour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Najoua%22%2C%22lastName%22%3A%22El%20Helali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Reibel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Chavanet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%20Moxifloxacin%20retains%20partial%20activity%20against%20some%20fluoroquinolone-resistant%20mutants%20of%20Mycobacterium%20tuberculosis.%20Levofloxacin%20is%20presumed%20to%20be%20as%20active%20as%20moxifloxacin%20against%20drug-susceptible%20tuberculosis%20and%20to%20have%20a%20better%20safety%20profile.Objectives%3A%20To%20compare%20the%20in%20vivo%20activity%20of%20levofloxacin%20and%20moxifloxacin%20against%20M.%20tuberculosis%20strains%20with%20various%20levels%20of%20fluoroquinolone%20resistance.Methods%3A%20BALB%5C%2Fc%20mice%20were%20intravenously%20infected%20with%20106M.%20tuberculosis%20H37Rv%20and%20three%20isogenic%20mutants%3A%20GyrA%20A90V%2C%20GyrB%20E540A%20and%20GyrB%20A543V.%20Treatment%20with%2050%20or%20100%5Cu2009mg%5C%2Fkg%20levofloxacin%20and%2060%20or%2066%5Cu2009mg%5C%2Fkg%20moxifloxacin%20was%20given%20orally%20every%206%5Cu2009h%2C%20for%204%5Cu2009weeks.Results%3A%20Levofloxacin%2050%20and%20100%5Cu2009mg%5C%2Fkg%20q6h%20and%20moxifloxacin%2060%20and%2066%5Cu2009mg%5C%2Fkg%20q6h%20generated%20AUCs%20in%20mice%20equivalent%20to%20those%20of%20levofloxacin%20750%20and%201000%5Cu2009mg%5C%2Fday%20and%20moxifloxacin%20400%20and%20800%5Cu2009mg%5C%2Fday%2C%20respectively%2C%20in%20humans.%20Moxifloxacin%2060%20and%2066%5Cu2009mg%5C%2Fkg%20q6h%20had%20bactericidal%20activity%20against%20strain%20H37Rv%20%28MIC%5Cu2009%5Cu2264%5Cu20090.25%5Cu2009mg%5C%2FL%29%20and%20mutants%20GyrB%20E540A%20and%20GyrB%20A543V%20%28MIC%5Cu2009%3D%5Cu20090.5%5Cu2009mg%5C%2FL%29.%20Against%20mutant%20GyrA%20A90V%20%28MIC%5Cu2009%3D%5Cu20092%5Cu2009mg%5C%2FL%29%2C%20moxifloxacin%2060%5Cu2009mg%5C%2Fkg%20q6h%20did%20not%20prevent%20bacillary%20growth%2C%20whereas%2066%5Cu2009mg%5C%2Fkg%20q6h%20had%20bacteriostatic%20activity.%20Levofloxacin%2050%5Cu2009mg%5C%2Fkg%20q6h%20had%20bactericidal%20activity%20against%20H37Rv%20%28MIC%5Cu2009%5Cu2264%5Cu20090.25%5Cu2009mg%5C%2FL%29%20but%20not%20against%20the%20mutant%20strains.%20Levofloxacin%20100%5Cu2009mg%5C%2Fkg%20q6h%20had%20bactericidal%20activity%20against%20H37Rv%20and%20mutants%20GyrB%20E540A%20%28MIC%5Cu2009%3D%5Cu20090.5%5Cu2009mg%5C%2FL%29%20and%20GyrB%20A543V%20%28MIC%3D%5Cu20091%5Cu2009mg%5C%2FL%29%20but%20not%20against%20mutant%20GyrA%20A90V%20%28MIC%5Cu2009%3D%5Cu20094%5Cu2009mg%5C%2FL%29.Conclusions%3A%20All%20mutations%20reduced%20fluoroquinolone%20activity%2C%20even%20those%20classified%20as%20susceptible%20according%20to%20phenotypic%20tests.%20High-dose%20levofloxacin%20is%20less%20effective%20than%20high-dose%20moxifloxacin%20against%20both%20fluoroquinolone-resistant%20and%20-susceptible%20M.%20tuberculosis%20strains%20in%20mice.%22%2C%22date%22%3A%222017%5C%2F08%5C%2F01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fjac%5C%2Fdkx150%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fjac%5C%2Farticle%5C%2F72%5C%2F8%5C%2F2326%5C%2F3849381%5C%2FAre-moxifloxacin-and-levofloxacin-equally%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%220305-7453%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-08-02T14%3A41%3A06Z%22%7D%7D%5D%7D
“Are Moxifloxacin and Levofloxacin Equally Effective to Treat XDR Tuberculosis?” by Thomas Maitre et al. Journal of Antimicrobial Chemotherapy. 72, no. 8 (August 1, 2017). https://doi.org/10.1093/jac/dkx150.
2016
Cliquer ici pour toutes les publications du CNR-MyRMA en 2016
1368488
{1368488:W4SXQV97}
1
art-libraries-society-of-north-america-arlisna-reviews
50
default
235
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22W4SXQV97%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bernard%20et%20al.%22%2C%22parsedDate%22%3A%222016-09-07%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26%23x201C%3BIn%20Vivo%20Mycobacterium%20Tuberculosis%20Fluoroquinolone%20Resistance%20Emergence%3A%20A%20Complex%20Phenomenon%20Poorly%20Detected%20by%20Current%20Diagnostic%20Tests%26%23x201D%3B%20by%20Christine%20Bernard%20et%20al.%20%26lt%3Bi%26gt%3BThe%20Journal%20of%20Antimicrobial%20Chemotherapy%26lt%3B%5C%2Fi%26gt%3B%2C%20September%207%2C%202016.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdkw344%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdkw344%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22In%20vivo%20Mycobacterium%20tuberculosis%20fluoroquinolone%20resistance%20emergence%3A%20a%20complex%20phenomenon%20poorly%20detected%20by%20current%20diagnostic%20tests%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Chauffour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20Heteroresistance%2C%20described%20both%20in%20terms%20of%20various%20point%20mutations%20resulting%20in%20different%20levels%20of%20resistance%20and%20in%20terms%20of%20a%20mixture%20of%20mutant%20and%20WT%20bacilli%2C%20is%20identified%20in%20up%20to%20one-third%20of%20fluoroquinolone%20%28FQ%29-resistant%20Mycobacterium%20tuberculosis%20isolates.%20Heteroresistance%20is%20a%20challenge%20for%20current%20phenotypic%20and%20genotypic%20susceptibility%20testing%20%28DST%29%20regimes.%20We%20aimed%20to%20compare%20the%20performances%20of%20different%20phenotypic%20and%20genotypic%20DST%20in%20the%20context%20of%20FQ%20heteroresistance%20by%20mimicking%2C%20in%20a%20murine%20model%2C%20the%20course%20of%20selection%20of%20FQ%20resistance%20during%20treatment.%5CnMETHODS%3A%20The%20capacity%20of%20different%20phenotypic%20DST%20%5BLowenstein-Jensen%20%28LJ%29%20medium%20containing%20either%202%20mg%5C%2FL%20ofloxacin%20or%200.5%2C%201%20or%202%20mg%5C%2FL%20moxifloxacin%5D%20and%20genotypic%20DST%20%28gyrA%5C%2FB%20Sanger%20sequencing%29%20to%20detect%20FQ%20resistance%20was%20analysed.%5CnRESULTS%3A%20Ninety-seven%20percent%20of%20mice%20harboured%20a%20heterogeneous%20population.%20The%20proportion%20of%20mice%20in%20which%20FQ%20resistance%20was%20detected%20varied%20according%20to%20the%20medium%20used%20%2897%25%20for%200.5%20mg%5C%2FL%20moxifloxacin%2C%2080%25%20for%202%20mg%5C%2FL%20ofloxacin%2C%2047%25%20for%201%20mg%5C%2FL%20moxifloxacin%20and%2025%25%20for%202%20mg%5C%2FL%20moxifloxacin%29.%20Compared%20with%20phenotypic%20DST%2C%20genotypic%20DST%20had%20a%20low%20sensitivity%20for%20detection%20of%20resistance%20%2833%25%29.%5CnCONCLUSIONS%3A%20Our%20study%20shows%20the%20in%20vivo%20complexity%20of%20FQ%20resistance%20emergence%20and%20the%20poor%20sensitivity%20of%20Sanger%20DNA%20sequencing%20for%20detection%20of%20heteroresistance.%20Our%20data%20support%20the%20use%20of%200.5%20mg%5C%2FL%20moxifloxacin%20in%20LJ%20for%20detection%20of%20FQ%20resistance%2C%20but%20not%20the%20recent%20increase%20in%20the%20ofloxacin%20critical%20concentration%20from%202%20to%204%20mg%5C%2FL%20given%20in%20the%20WHO%20recommendations.%22%2C%22date%22%3A%22Sep%207%2C%202016%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fjac%5C%2Fdkw344%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221460-2091%22%2C%22language%22%3A%22ENG%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-01-08T18%3A02%3A04Z%22%7D%7D%5D%7D
“In Vivo Mycobacterium Tuberculosis Fluoroquinolone Resistance Emergence: A Complex Phenomenon Poorly Detected by Current Diagnostic Tests” by Christine Bernard et al. The Journal of Antimicrobial Chemotherapy, September 7, 2016. https://doi.org/10.1093/jac/dkw344.
2015
Cliquer ici pour toutes les publications du CNR-MyRMA en 2015
1368488
{1368488:9FTWPRVV}
1
art-libraries-society-of-north-america-arlisna-reviews
50
default
236
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%229FTWPRVV%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guglielmetti%20et%20al.%22%2C%22parsedDate%22%3A%222015-01-15%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26%23x201C%3BCompassionate%20Use%20of%20Bedaquiline%20for%20the%20Treatment%20of%20Multidrug-Resistant%20and%20Extensively%20Drug-Resistant%20Tuberculosis%3A%20Interim%20Analysis%20of%20a%20French%20Cohort%26%23x201D%3B%20by%20Lorenzo%20Guglielmetti%20et%20al.%20%26lt%3Bi%26gt%3BClinical%20Infectious%20Diseases%26lt%3B%5C%2Fi%26gt%3B.%2060%2C%20no.%202%20%28January%2015%2C%202015%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciu786%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciu786%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Compassionate%20Use%20of%20Bedaquiline%20for%20the%20Treatment%20of%20Multidrug-Resistant%20and%20Extensively%20Drug-Resistant%20Tuberculosis%3A%20Interim%20Analysis%20of%20a%20French%20Cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%20Le%22%2C%22lastName%22%3A%22D%5Cu00fb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beno%5Cu00eet%22%2C%22lastName%22%3A%22Henry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diane%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22M%5Cu00e9tivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Andrejak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Chadelat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Dautzenberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Raskine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Rivoire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Appere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Assouline%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Borie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Boukari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Caseris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Douadi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Dumoulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Duval%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20F.%22%2C%22lastName%22%3A%22Faucher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Gallien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Godet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Le%22%2C%22lastName%22%3A%22Grusse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Lopes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Meynard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Naccache%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Philippe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Richaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Saad%22%7D%5D%2C%22abstractNote%22%3A%22Background.%20Bedaquiline%20is%20a%20new%20antibiotic%20that%20was%20approved%20for%20the%20treatment%20of%20multidrug-resistant%20%28MDR%29%20tuberculosis.%20We%20aimed%20to%20evaluate%20the%20short-term%20microbiological%20efficacy%20and%20the%20tolerability%20profile%20of%20bedaquiline.%5CnMethods.%20We%20performed%20a%20retrospective%20cohort%20study%20among%20patients%20with%20MDR%20tuberculosis%20receiving%20bedaquiline%20for%20compassionate%20use%20between%20January%202010%20and%20July%202013%20and%20evaluated%20at%206%20months%20of%20bedaquiline%20treatment.%5CnResults.%20A%20total%20of%2035%20patients%20with%20MDR%20tuberculosis%20were%20included%20in%20the%20study.%20Nineteen%20%2854%25%29%20had%20extensively%20drug-resistant%20%28XDR%29%20tuberculosis%2C%20and%2014%20%2840%25%29%20had%20isolates%20resistant%20to%20fluoroquinolones%20%28Fqs%29%20or%20second-line%20injectables.%20Bedaquiline%20was%20associated%20with%20a%20median%20of%204%20%28range%2C%202%5Cu20135%29%20other%20drugs%2C%20including%20linezolid%20in%2033%20%2894%25%29%20cases.%20At%206%20months%20of%20bedaquiline%20treatment%2C%20culture%20conversion%20was%20achieved%20in%2028%20of%2029%20%2897%25%29%20cases%20with%20culture-positive%20pulmonary%20tuberculosis%20at%20bedaquiline%20initiation.%20Median%20time%20to%20culture%20conversion%20was%2085%20days%20%28range%2C%208%5Cu2013235%20days%29.%20Variables%20independently%20associated%20with%20culture%20conversion%20were%20treatment%20with%20a%20Fq%20%28P%20%3D%20.01%29%2C%20absence%20of%20lung%20cavities%20%28P%20%26lt%3B%20.001%29%2C%20and%20absence%20of%20hepatitis%20C%20virus%20infection%20%28P%20%3D%20.001%29.%20A%20total%20of%207%20patients%20%2820%25%29%20experienced%20a%20%5Cu226560-ms%20increase%20in%20QT%20interval%2C%20leading%20to%20bedaquiline%20discontinuation%20in%202%20%286%25%29%20cases.%20Severe%20liver%20enzyme%20elevation%20occurred%20in%202%20patients%20%286%25%29.%20During%20the%20study%20period%2C%201%20death%20%283%25%29%20occurred%20and%20was%20reported%20as%20unrelated%20to%20tuberculosis%20or%20antituberculosis%20treatment.%5CnConclusions.%20The%20use%20of%20bedaquiline%20combined%20with%20other%20active%20drugs%20has%20the%20potential%20to%20achieve%20high%20culture%20conversion%20rates%20in%20complicated%20MDR%20and%20XDR%20tuberculosis%20cases%2C%20with%20a%20reassuring%20safety%20profile%20at%206%20months%20of%20treatment.%22%2C%22date%22%3A%222015-01-15%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciu786%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fcid.oxfordjournals.org%5C%2Fcontent%5C%2F60%5C%2F2%5C%2F188%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221058-4838%2C%201537-6591%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-03-26T17%3A55%3A16Z%22%7D%7D%5D%7D
“Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort” by Lorenzo Guglielmetti et al. Clinical Infectious Diseases. 60, no. 2 (January 15, 2015). https://doi.org/10.1093/cid/ciu786.
2014
Cliquer ici pour toutes les publications du CNR-MyRMA en 2014
1368488
{1368488:F23JKI8Q}
1
art-libraries-society-of-north-america-arlisna-reviews
50
default
237
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22F23JKI8Q%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brossier%20et%20al.%22%2C%22parsedDate%22%3A%222014-11-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26%23x201C%3BComparison%20of%20a%20Semiautomated%20Commercial%20Repetitive-Sequence-Based%20PCR%20Method%20with%20Spoligotyping%2C%2024-Locus%20Mycobacterial%20Interspersed%20Repetitive-Unit%26%23×2013%3BVariable-Number%20Tandem-Repeat%20Typing%2C%20and%20Restriction%20Fragment%20Length%20Polymorphism-Based%20Analysis%20of%20IS6110%20for%20Mycobacterium%20Tuberculosis%20Typing%26%23x201D%3B%20by%20F.%20Brossier%20et%20al.%20%26lt%3Bi%26gt%3BJournal%20of%20Clinical%20Microbiology%26lt%3B%5C%2Fi%26gt%3B.%2052%2C%20no.%2011%20%28November%201%2C%202014%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FJCM.02226-14%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FJCM.02226-14%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparison%20of%20a%20Semiautomated%20Commercial%20Repetitive-Sequence-Based%20PCR%20Method%20with%20Spoligotyping%2C%2024-Locus%20Mycobacterial%20Interspersed%20Repetitive-Unit%5Cu2013Variable-Number%20Tandem-Repeat%20Typing%2C%20and%20Restriction%20Fragment%20Length%20Polymorphism-Based%20Analysis%20of%20IS6110%20for%20Mycobacterium%20tuberculosis%20Typing%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Sola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Millot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Sougakoff%22%7D%5D%2C%22abstractNote%22%3A%22Fifty-two%20multidrug-resistant%20isolates%20of%20Mycobacterium%20tuberculosis%20representative%20of%20the%20currently%20predominant%20lineages%20in%20France%20were%20analyzed%20using%20repetitive-sequence-based%20PCR%20%28rep-PCR%29%20DiversiLab%20%28DL%29%2C%20spoligotyping%2C%2024-locus%20mycobacterial%20interspersed%20repetitive-unit%5Cu2013variable-number%20tandem-repeat%20typing%20%28MIRU-VNTR%29%2C%20and%20restriction%20fragment%20length%20polymorphism%20of%20IS6110%20%28IS6110-RFLP%29.%20DL%2C%20as%20opposed%20to%20MIRU-VNTR%20and%20IS6110-RFLP%20analysis%2C%20did%20not%20allow%20discrimination%20among%20half%20of%20the%20isolates%2C%20an%20indication%20of%20comparatively%20lower%20resolving%20power.%22%2C%22date%22%3A%2211%5C%2F01%5C%2F2014%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1128%5C%2FJCM.02226-14%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fjcm.asm.org%5C%2Fcontent%5C%2F52%5C%2F11%5C%2F4082%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%220095-1137%2C%201098-660X%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-04-27T17%3A08%3A24Z%22%7D%7D%5D%7D
“Comparison of a Semiautomated Commercial Repetitive-Sequence-Based PCR Method with Spoligotyping, 24-Locus Mycobacterial Interspersed Repetitive-Unit–Variable-Number Tandem-Repeat Typing, and Restriction Fragment Length Polymorphism-Based Analysis of IS6110 for Mycobacterium Tuberculosis Typing” by F. Brossier et al. Journal of Clinical Microbiology. 52, no. 11 (November 1, 2014). https://doi.org/10.1128/JCM.02226-14.
2013
Cliquer ici pour toutes les publications du CNR-MyRMA en 2013
1368488
{1368488:HRKPMGKG}
1
art-libraries-society-of-north-america-arlisna-reviews
50
default
238
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22HRKPMGKG%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Veziris%20et%20al.%22%2C%22parsedDate%22%3A%222013-11-14%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26%23x201C%3BResistance%20of%20M.%20Leprae%20to%20Quinolones%3A%20A%20Question%20of%20Relativity%3F%26%23x201D%3B%20by%20Nicolas%20Veziris%20et%20al.%20%26lt%3Bi%26gt%3BPLoS%20Negl%20Trop%20Dis%26lt%3B%5C%2Fi%26gt%3B.%207%2C%20no.%2011%20%28November%2014%2C%202013%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pntd.0002559%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pntd.0002559%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Resistance%20of%20M.%20leprae%20to%20Quinolones%3A%20A%20Question%20of%20Relativity%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurelie%22%2C%22lastName%22%3A%22Chauffour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Escolano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Henquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Masanori%22%2C%22lastName%22%3A%22Matsuoka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%5D%2C%22abstractNote%22%3A%22Author%20SummaryAlthough%20there%20is%20efficient%20multidrug%20therapy%20to%20cure%20leprosy%2C%20the%20transmission%20of%20M.%20leprae%20is%20still%20active%2C%20leading%20to%20219%2C000%20new%20cases%20in%202011.%20Drug%20resistant%20leprosy%20has%20been%20described%20and%20may%20prevent%20eradication%20of%20the%20disease%2C%20notably%20multidrug%20resistant%20defined%20as%20resistance%20to%20rifampin%2C%20dapsone%20and%20fluoroquinolones%20%28FQ%29.%20Resistance%20to%20FQ%20is%20due%20to%20mutations%20in%20DNA%20gyrase.%20We%20used%20a%20mouse%20model%20to%20measure%20the%20impact%20of%20DNA%20gyrase%20mutations%20on%20in%20vivo%20FQ%20activity.%20All%20the%20FQ%20tested%20showed%20in%20vivo%20activity%20against%20the%20mutant%20tested%20%28A91V%20mutant%20in%20subunit%20A%20of%20DNA%20gyrase%29.%20However%2C%20whereas%20ofloxacin%20was%20less%20active%20than%20the%20control%20treatment%20clarithromycin%2C%20it%20appeared%20that%20latter%20generation%20fluoroquinolones%20moxifloxacin%20and%20garenoxacin%20were%20as%20active%20as%20clarithromycin.%20Our%20results%20demonstrate%20that%20DNA%20gyrase%20mutation%20is%20not%20synonymous%20of%20total%20lack%20of%20in%20vivo%20FQ%20activity%20against%20M.%20leprae.%20Therefore%2C%20as%20for%20M.%20tuberculosis%2C%20in%20vivo%20studies%20are%20mandatory%20in%20order%20to%20measure%20the%20impact%20of%20DNA%20gyrase%20mutations%20on%20treatment%20efficacy%20against%20M.%20leprae.%22%2C%22date%22%3A%22November%2014%2C%202013%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pntd.0002559%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fdx.doi.org%5C%2F10.1371%5C%2Fjournal.pntd.0002559%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%22%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222015-07-20T16%3A28%3A18Z%22%7D%7D%5D%7D
“Resistance of M. Leprae to Quinolones: A Question of Relativity?” by Nicolas Veziris et al. PLoS Negl Trop Dis. 7, no. 11 (November 14, 2013). https://doi.org/10.1371/journal.pntd.0002559.
2012
Cliquer ici pour toutes les publications du CNR-MyRMA en 2012 / click here
1368488
{1368488:JT79M536}
1
art-libraries-society-of-north-america-arlisna-reviews
50
default
239
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22JT79M536%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pantel%20et%20al.%22%2C%22parsedDate%22%3A%222012-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26%23x201C%3BExtending%20the%20Definition%20of%20the%20GyrB%20Quinolone%20Resistance-Determining%20Region%20in%20Mycobacterium%20Tuberculosis%20DNA%20Gyrase%20for%20Assessing%20Fluoroquinolone%20Resistance%20in%20M.%20Tuberculosis%26%23x201D%3B%20by%20Alix%20Pantel%20et%20al.%20%26lt%3Bi%26gt%3BAntimicrobial%20Agents%20and%20Chemotherapy%26lt%3B%5C%2Fi%26gt%3B.%2056%2C%20no.%204%20%28April%202012%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.06272-11%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.06272-11%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Extending%20the%20Definition%20of%20the%20GyrB%20Quinolone%20Resistance-Determining%20Region%20in%20Mycobacterium%20tuberculosis%20DNA%20Gyrase%20for%20Assessing%20Fluoroquinolone%20Resistance%20in%20M.%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alix%22%2C%22lastName%22%3A%22Pantel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephanie%22%2C%22lastName%22%3A%22Petrella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvaine%22%2C%22lastName%22%3A%22Bastian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudine%22%2C%22lastName%22%3A%22Mayer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%5D%2C%22abstractNote%22%3A%22Fluoroquinolone%20%28FQ%29%20resistance%20is%20emerging%20in%20Mycobacterium%20tuberculosis.%20The%20main%20mechanism%20of%20FQ%20resistance%20is%20amino%20acid%20substitution%20within%20the%20quinolone%20resistance-determining%20region%20%28QRDR%29%20of%20the%20GyrA%20subunit%20of%20DNA%20gyrase%2C%20the%20sole%20FQ%20target%20in%20M.%20tuberculosis.%20However%2C%20substitutions%20in%20GyrB%20whose%20implication%20in%20FQ%20resistance%20is%20unknown%20are%20increasingly%20being%20reported.%20The%20present%20study%20clarified%20the%20role%20of%20four%20GyrB%20substitutions%20identified%20in%20M.%20tuberculosis%20clinical%20strains%2C%20two%20located%20in%20the%20QRDR%20%28D500A%20and%20N538T%29%20and%20two%20outside%20the%20QRDR%20%28T539P%20and%20E540V%29%2C%20in%20FQ%20resistance.%20We%20measured%20FQ%20MICs%20and%20also%20DNA%20gyrase%20inhibition%20by%20FQs%20in%20order%20to%20unequivocally%20clarify%20the%20role%20of%20these%20mutations%20in%20FQ%20resistance.%20Wild-type%20GyrA%2C%20wild-type%20GyrB%2C%20and%20mutant%20GyrB%20subunits%20produced%20from%20engineered%20gyrB%20alleles%20by%20mutagenesis%20were%20overexpressed%20in%20Escherichia%20coli%2C%20purified%20to%20homogeneity%2C%20and%20used%20to%20reconstitute%20highly%20active%20gyrase%20complexes.%20MICs%20and%20DNA%20gyrase%20inhibition%20were%20determined%20for%20moxifloxacin%2C%20gatifloxacin%2C%20ofloxacin%2C%20levofloxacin%2C%20and%20enoxacin.%20All%20these%20substitutions%20are%20clearly%20implicated%20in%20FQ%20resistance%2C%20underlining%20the%20presence%20of%20a%20hot%20spot%20region%20housing%20most%20of%20the%20GyrB%20substitutions%20implicated%20in%20FQ%20resistance%20%28residues%20NTE%2C%20538%20to%20540%29.%20These%20findings%20help%20us%20to%20refine%20the%20definition%20of%20GyrB%20QRDR%2C%20which%20is%20extended%20to%20positions%20500%20to%20540.%22%2C%22date%22%3A%222012-4%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1128%5C%2FAAC.06272-11%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC3318379%5C%2F%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%220066-4804%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222015-07-20T16%3A54%3A20Z%22%7D%7D%5D%7D
“Extending the Definition of the GyrB Quinolone Resistance-Determining Region in Mycobacterium Tuberculosis DNA Gyrase for Assessing Fluoroquinolone Resistance in M. Tuberculosis” by Alix Pantel et al. Antimicrobial Agents and Chemotherapy. 56, no. 4 (April 2012). https://doi.org/10.1128/AAC.06272-11.
2011
Cliquer ici pour toutes les publications du CNR-MyRMA en 2011 / click here
1368488
{1368488:6RTU8WMI}
1
art-libraries-society-of-north-america-arlisna-reviews
50
default
794
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%226RTU8WMI%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Petrella%20et%20al.%22%2C%22parsedDate%22%3A%222011-01-24%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26%23x201C%3BCrystal%20Structure%20of%20the%20Pyrazinamidase%20of%20Mycobacterium%20Tuberculosis%26%23x202F%3B%3A%20Insights%20into%20Natural%20and%20Acquired%20Resistance%20to%20Pyrazinamide%26%23x201D%3B%20by%20St%26%23xE9%3Bphanie%20Petrella%20et%20al.%20%26lt%3Bi%26gt%3BPLOS%20ONE%26lt%3B%5C%2Fi%26gt%3B.%206%2C%20no.%201%20%28January%2024%2C%202011%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0015785%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0015785%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Crystal%20Structure%20of%20the%20Pyrazinamidase%20of%20Mycobacterium%20tuberculosis%20%3A%20Insights%20into%20Natural%20and%20Acquired%20Resistance%20to%20Pyrazinamide%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Petrella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Gelus-Ziental%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Maudry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Laurans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachid%22%2C%22lastName%22%3A%22Boudjelloul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%5D%2C%22abstractNote%22%3A%22Pyrazinamidase%20%28PncA%29%20activates%20the%20first-line%20antituberculous%20drug%20pyrazinamide%20into%20pyrazinoic%20acid.%20The%20crystal%20structure%20of%20the%20%20Mycobacterium%20tuberculosis%20%20PncA%20protein%20has%20been%20determined%2C%20showing%20significant%20differences%20in%20the%20substrate%20binding%20cavity%20when%20compared%20to%20the%20pyrazinamidases%20from%20%20Pyrococcus%20horikoshii%20%20and%20%20Acinetobacter%20baumanii%20.%20In%20%20M.%20tuberculosis%20%2C%20this%20region%20was%20found%20to%20hold%20a%20Fe%202%2B%20%20ion%20coordinated%20by%20one%20aspartate%20and%20three%20histidines%2C%20one%20of%20them%20corresponding%20to%20His57%20which%20is%20replaced%20by%20Asp%20in%20%20Mycobacterium%20bovis%20%2C%20a%20species%20naturally%20resistant%20to%20pyrazinamide.%20The%20binding%20cavity%20also%20contains%20a%20Cys138-Asp8-Lys96%20motif%20evocating%20a%20cysteine-based%20catalytic%20mechanism.%20Mutants%20have%20been%20constructed%20and%20investigated%20by%20kinetic%20and%20thermal%20shift%20assays%2C%20highlighting%20the%20importance%20of%20protein%20folding%20and%20thermal%20stability%20in%20the%20pyrazinamidase%20activity.%22%2C%22date%22%3A%2224%20janv.%202011%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pone.0015785%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fjournals.plos.org%5C%2Fplosone%5C%2Farticle%3Fid%3D10.1371%5C%2Fjournal.pone.0015785%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221932-6203%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-04-25T05%3A39%3A38Z%22%7D%7D%5D%7D
“Crystal Structure of the Pyrazinamidase of Mycobacterium Tuberculosis : Insights into Natural and Acquired Resistance to Pyrazinamide” by Stéphanie Petrella et al. PLOS ONE. 6, no. 1 (January 24, 2011). https://doi.org/10.1371/journal.pone.0015785.
2010
Cliquer ici pour toutes les publications du CNR-MyRMA en 2010 / click here
1368488
{1368488:5KB9RK5J}
1
art-libraries-society-of-north-america-arlisna-reviews
50
default
799
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%225KB9RK5J%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brossier%20et%20al.%22%2C%22parsedDate%22%3A%222010-05-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26%23x201C%3BDetection%20by%20GenoType%20MTBDRsl%20Test%20of%20Complex%20Mechanisms%20of%20Resistance%20to%20Second-Line%20Drugs%20and%20Ethambutol%20in%20Multidrug-Resistant%20Mycobacterium%20Tuberculosis%20Complex%20Isolates%26%23x201D%3B%20by%20Florence%20Brossier%20et%20al.%20%26lt%3Bi%26gt%3BJournal%20of%20Clinical%20Microbiology%26lt%3B%5C%2Fi%26gt%3B.%2048%2C%20no.%205%20%28May%201%2C%202010%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FJCM.01947-09%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FJCM.01947-09%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Detection%20by%20GenoType%20MTBDRsl%20Test%20of%20Complex%20Mechanisms%20of%20Resistance%20to%20Second-Line%20Drugs%20and%20Ethambutol%20in%20Multidrug-Resistant%20Mycobacterium%20tuberculosis%20Complex%20Isolates%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%5D%2C%22abstractNote%22%3A%22The%20GenoType%20MTBDRsl%20test%20rapidly%20detects%20resistance%20to%20ethambutol%2C%20fluoroquinolones%2C%20and%20second-line%20aminoglycosides%20%28amikacin%20and%20kanamycin%29%20and%20cyclic%20peptide%20%28capreomycin%29%20in%20Mycobacterium%20tuberculosis.%20A%20set%20of%2041%20multidrug-resistant%20%28MDR%29%20M.%20tuberculosis%20strains%2C%208%20extensively%20drug-resistant%20%28XDR%29%20M.%20tuberculosis%20strains%2C%20and%203%20non-MDR%20M.%20tuberculosis%20strains%20were%20tested%20by%20the%20MTBDRsl%20test%20and%20by%20DNA%20sequencing%20of%20the%20resistance-determining%20regions%20in%20gyrA%20and%20gyrB%20%28fluoroquinolones%20%5BFQ%5D%29%2C%20rpsL%20%28streptomycin%29%2C%20rrs%20and%20tlyA%20%28aminoglycosides%20and%5C%2For%20cyclic%20peptide%29%2C%20and%20embB%20%28ethambutol%29.%20The%20sensitivity%20and%20specificity%20of%20the%20MTBDRsl%20test%20were%20as%20follows%3A%2087%25%20and%2096%25%2C%20respectively%2C%20for%20fluoroquinolones%3B%20100%25%20for%20both%20for%20amikacin%3B%2077%25%20and%20100%25%2C%20respectively%2C%20for%20kanamycin%2C%2080%25%20and%2098%25%2C%20respectively%2C%20for%20capreomycin%3B%20and%2057%25%20and%2092%25%2C%20respectively%2C%20for%20ethambutol.%20Analysis%20of%20the%20discrepant%20results%20indicated%20that%20three%20FQ-resistant%20strains%20%28including%20one%20XDR%20strain%29%20with%20mutations%20in%20gyrB%20were%20missed%20by%20the%20MTBDRsl%20test%20and%20that%20one%20FQ-susceptible%20strain%2C%20identified%20as%20resistant%20by%20the%20MTBDRsl%20test%2C%20had%20a%20double%20mutation%20%28T80A-A90G%29%20in%20GyrA%20that%20did%20not%20confer%20resistance%20to%20FQ.%20Five%20strains%20%28including%20two%20XDR%20strains%29%20without%20mutations%20in%20rrs%20were%20monoresistant%20to%20aminoglycosides%20or%20cyclic%20peptide%20and%20were%20missed%20by%20the%20MTBDRsl%20test.%20Finally%2C%2012%5C%2F28%20ethambutol-resistant%20strains%20had%20no%20mutation%20at%20codon%20306%20in%20embB%2C%20while%202%5C%2F24%20ethambutol-susceptible%20strains%20had%20such%20a%20mutation.%20In%20conclusion%2C%20the%20MTBDRsl%20test%20efficiently%20detects%20the%20most%20common%20mutations%20involved%20in%20resistance%20to%20fluoroquinolones%2C%20aminoglycosides%5C%2Fcyclic%20peptide%2C%20and%20ethambutol%20and%20accurately%20assesses%20susceptibility%20to%20amikacin.%20However%2C%20due%20to%20mutations%20not%20included%20in%20the%20test%20%28particularly%20in%20gyrB%29%20or%20resistance%20mechanisms%20not%20yet%20characterized%20%28particularly%20those%20related%20to%20ethambutol%20resistance%20and%20to%20monoresistance%20to%20aminoglycosides%20or%20cyclic%20peptide%29%2C%20the%20wild-type%20results%20yielded%20by%20the%20MTBDRsl%20test%20should%20be%20confirmed%20by%20drug%20susceptibility%20testing.%22%2C%22date%22%3A%2205%5C%2F01%5C%2F2010%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1128%5C%2FJCM.01947-09%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fjcm.asm.org%5C%2Fcontent%5C%2F48%5C%2F5%5C%2F1683%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%220095-1137%2C%201098-660X%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222013-09-02T12%3A22%3A37Z%22%7D%7D%5D%7D
“Detection by GenoType MTBDRsl Test of Complex Mechanisms of Resistance to Second-Line Drugs and Ethambutol in Multidrug-Resistant Mycobacterium Tuberculosis Complex Isolates” by Florence Brossier et al. Journal of Clinical Microbiology. 48, no. 5 (May 1, 2010). https://doi.org/10.1128/JCM.01947-09.
